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A growing body of evidence suggests that tumor-associated macrophages are 
deeply involved in the hepatocellular carcinoma proliferation and account for the 
large proportion of infiltrated cells in tumor tissues and play a major role in promotion 
of tumor growth. On the other hand, studies have demonstrated that Toxoplasma 
gondii virulence-associated molecule of dense granule protein (ToxoGRA15II) 
tends to induce classically activated macrophages (M1) differentiation. Thus, we 
explored the M1 induced by ToxoGRA15II in  vitro and its inhibitory impact on the 
proliferation, invasion, and metastasis of hepatic carcinoma in murine model. Here, 
we constructed recombinant plasmid of pegfp-gra15II and subsequently ligate it to 
lentivirus (Lv) vector, with which RAW264.7 was transfected. The results showed 
that the transfected macrophages were polarized to M1. Coculture of the M1 with 
Hepa1-6 cells showed a remarkable inhibition of migration and invasion of the tumor 
cells and decreased expressions of matrix metalloproteinase (MMP)-9 and MMP-2 
without notable apoptosis of Hepa1-6 cells. Subsequently, ToxoGRA15II-polarized 
macrophages inoculated to tumor-bearing C57BL/6 mice were seen in both spleen 
and tumor tissues, and tumor growth was sharply restricted. Particularly, interleukin-6 
(IL-6) expression, which is closely associated with the cancer malignant behaviors, was 
significantly dampened in tumor tissues. In addition, expression of TNF-α and IL-12 
mRNAs was increased, whereas IL-6 and interleukin-10 mRNAs were downregulated 
in splenocytes. Our results indicate that the effector molecule of ToxoGRA15II may 
induce macrophage polarization to M1 that has a restrictive effect on tumor growth via 
its related cytokines profile in tumor and spleen tissues. Besides, ToxoGRA15II, due 
to its early activation of specified cell population and non-toxicity to mammalians, has 
a potential value for a novel therapeutic strategy of enhancing host innate immunity 
against tumor development.
Keywords: Toxoplasma gondii, dense granule protein gra15, hepatocellular carcinoma, tumor-associated 
macrophages, polarization
2Li et al. ToxoGRA15II-Polarized Macrophages Inhibit HCC Growth
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 137
inTrODUcTiOn
Hepatocellular carcinoma (HCC) ranks in the top five diagnosed 
malignant cancers in men and in the seven in women (1, 2). 
In the last decades, the mortality of liver cancer has not been 
noticeably reduced although phenomenal advances have been 
made in the technologies of diagnosis and treatments, such as 
surgery, radiation, and chemotherapy. Recently, immunotherapy 
is considered to be a crucial part of cancer treatments (3). It has 
been known that the cross talk between the tumor cells and their 
surrounding microenvironment is pivotal for HCC development. 
In the tumor microenvironment, tumor-associated macrophages 
(TAMs) infiltrate into tumor stroma and facilitate tumor pro-
liferation, survival, and migration (4). Plasticity is a hallmark 
of macrophages. It has been confirmed that macrophages have 
two different polarized states, one is the classically activated 
macrophages phenotype (M1) and the other is the alternatively 
activated macrophages phenotype (M2). The M1 induced by 
lipopolysaccharides (LPS) and Th1 cytokine interferon-γ (IFN-
γ) possess high antigen-presenting ability and secrete inducible 
nitric oxide synthase (iNOS), which lead to a high level nitric 
oxide (NO) killing of intracellular pathogens. In contrast, the 
M2 responding to Th2 cytokine interleukin-4, interleukin-10 
(IL-10), and interleukin-13 activation are capable of suppressing 
immune response (5–7). Affected by tumor microenvironment, 
TAMs can also be divided into M1 phenotype, which plays a role 
in antitumorigenic response, and M2 phenotype, which promotes 
tumorigenesis (6, 8, 9). Thus, TAMs are believed to be the key 
target in the immunotherapy.
The ability of various infections to inhibit tumor growth by 
modulating the host immune system has been previously proved. 
For example, malaria parasite infection, remarkably suppresses 
Lewis lung cancer growth through innate and adaptive antitumor 
response (10). Mice inoculated with both Toxoplasma and cancer 
cells presented significantly increased survival rates, CD8+ T cell 
proportion, IFN-γ mRNA expression levels, serum IgG2a titers, 
and inhibited angiogenesis when compared to the animals with 
only tumor cells plantation (11).
Toxoplasma gondii is an obligatory intracellular parasite that 
affects any warm-blood animals including humans. Several 
investigations indicate that approximately one-third of the 
world’s population is affected by T. gondii. The sexual life cycle 
of T. gondii is restricted to the intestinal epithelium of feline (12, 
13). Due to the immune surveillance of host, most immuno-
competent people infected with the parasite are asymptomatic. 
The parasite may exist in the cyst form and in the tissues of 
human body. In immunocompromised individuals, however, 
such as patients with AIDS and those who have received long-
term immunosuppressive treatments, latent T. gondii infection 
may lead to severe consequences of toxoplasmosis, mainly 
encephalitis (14).
Recent studies have showed that T. gondii strains have a 
rich genetic diversity in geographical regions around the world. 
Type I (RH, GT1), type II (PRU, ME49), and type III (CTG) 
are widely distributed in Europe and North America (15, 16). 
Though the three genotypes of Toxoplasma have been identified 
in the isolates from humans, the majority of human cases are 
associated with type II strains (17). These strains differ widely 
in virulence, persistence, and migratory capacity in mice (16). 
Besides its complex cellular structure, T. gondii has three main 
secretory organelles termed as microneme, rhoptry, and dense 
granule. These organelles are able to secrete polymorphic effec-
tor molecules into the host cytosol to modulate host signaling 
pathways and link to strain virulence. Macrophages infected 
with type II strain of Toxoplasma are classically activated. This 
is due to its dense granule protein GRA15II, which activates 
nuclear factor (NF)-κB, drives macrophage to M1 polariza-
tion, induces high expression of IL-12, stimulates NK and T 
cells secreting IFN-γ, and evokes Th1 type immune response 
(18–20). Interestingly, the virulence-associated effector of 
ToxoGRA15II may induce M1 phenotype polarization and 
alleviate fibrogenesis caused by schistosomiasis (21).
In the present study, we observed the mouse macrophage 
RAW264.7 cell line infected with lentiviral vectors containing 
gra15II, which was amplified from the T. gondii PRU strain. 
We found that the RAW264.7 cells were driven toward M1 
polarization. GRA15II-induced M1 were cocultured with the 
murine HCC heap1-6 cell line in transwell to clarify the in vitro 
effect of the skewed macrophage phenotype on proliferation, 
migration, invasion, and the expression changes of matrix 
metalloproteinases (MMPs). Moreover, the C57BL/6 mice were 
treated with activated M1 cells via high-pressure injection of 
the tail vein following hepa1-6 cells subcutaneous inoculation. 
The tumor volume, histopathology, TAMs, immunosuppres-
sive factors, and angiogenesis-related factors were detected, 
respectively.
MaTerials anD MeThODs
reagents
The following reagents were used in the study: Dulbecco’s modi-
fied Eagle’s medium (DMEM) and fetal bovine serum (FBS) were 
obtained from Wisent (Montreal, QC, Canada). Puromycin 
(PM), penicillin, and streptomycin were purchased from Sigma 
(St. Louis, MO, USA). SDS-polyacrylamide gel electrophoresis 
and 10% buffered neutral formaldehyde were purchased from 
Beyotime (Shanghai, China). Nitrocellulose membranes were 
provided by Millipore (Billerica, MA, USA). FITC-labeled 
anti-mouse F4/80, PE-conjugated anti-mouse programmed 
death ligand 1 (PD-L1), and PE-Cy5-labeled anti-mouse CD80 
monoclonal antibodies were obtained from eBioscience (San 
Diego CA, USA) for flow cytometry analysis. Antibodies against 
MMP-2, MMP-9, and GAPDH used for Western blotting were 
manufactured by Proteintech (Chicago, IL, USA). Rat anti-mouse 
F4/80, CD68, IL-10, TGF-β, VEGF, and anti-mouse major histo-
compatibility complex class II (MHCII) monoclonal antibodies 
that recognize cells from both BALB/c and C57 BL/6 mice were 
manufactured by Abcam (Cambridge, MA, USA) for immunohis-
tochemistry assays. The TNF-α enzyme-linked immunosorbent 
assay (ELISA) kit was provided by CUSABIO (Wuhan, China). 
The interleukin-6 (IL-6) ELISA kit was obtained from RayBiotech 
(Norcross GA, USA). The Greiss Reagent System determined for 
nitrite was purchased from Promega Biotech Company (Madison, 
WI, USA).
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Parasites, Plasmid construction, and 
lentvirus infection
Toxoplasma gondii tachyzoites of PRU (type II) strain were 
initially obtained by mouse passages with brain homogenate 
containing cysts. The open reading frame encoding TgGRA15II 
(omitted signal peptide of 1,500  bp, http://ToxoDB.org) was 
amplified through real-time (RT)-PCR from the total tachyzoites 
RNA, recombinant plasmids pEGFP-gra15II were constructed, 
and recombinant lentivirus (Lv) vectors (LV-pEGFP-gra15II) 
were obtained (21).
cell culture
The murine HCC cells, Hepa1-6, were purchased from the Chinese 
Academy of Sciences Cell Bank in Shanghai. The murine Mφ cell 
line, RAW264.7, was preserved in the laboratory. RAW264.7 cells 
transfected by LV-pEGFP-gra15II were named LV-gra15II-Mφ. 
The mock Lv-infected RAW264.7 cells were termed LV-Mφ. 
The two cell lines remain high in transfection efficiency when 
screened with PM. All of these cells were cultured in DMEM 
supplemented with 10–15% FBS and 1% penicillin–streptomycin 
at 37°C with 5% CO2.
Flow cytometry assay
The transfection and M1 surface marker analysis of mac-
rophages that express GRA15II were determined by flow 
cytometry. Briefly, single cell suspensions of the three groups 
of Mφ (LV-gra15II-Mφ, LV-Mφ, and Mφ) were washed in PBS 
containing 1% FBS and adjusted to 1 ×  106 cells per 100  µl 
PBS with 1% FBS, respectively. The cells were subjected to 
FITC-labeled anti-mouse F4/80, followed by PE-conjugated 
anti-mouse PD-L1, and PE-Cy5-labeled anti-mouse CD80 
for surface antigens staining. All cells were incubated with 
the antibodies at 4°C for 20  min in order to protect the cell 
from light and washed in PBS twice. Cells were analyzed 
with flow cytometry. Results were analyzed using FlowJo 
software.
MTs assay
The culture supernatants of LV-gra15II-Mφ, LV-Mφ, and Mφ, 
were applied to Hepa1-6 cell in vitro, and the Hepa1-6 viability 
was determined by MTS assay (22). MTS assay CellTiter 96 
Aqueous One Solution reagents were manufactured by Promega 
(Madison, WI, USA). Briefly, LV-gra15II-Mφ, LV-Mφ, and Mφ 
cells (2 ×  106) were separately cultured for 48 h, and then the 
supernatants were collected. Hepa1-6 cells were seeded in 96-well 
plates at a density of 1 × 104 cells per well in 100 μl DMEM sup-
plemented with 10% FBS for 12 h and then exposed to different 
supernatants for 48 h. At 4 h before culture termination, 20 μl 
of MTS reagent was added to the wells for 1 h incubation. The 
absorbance density was read on a 96-well plate reader (BioTek) 
at wavelength 490 nm.
Transwell assay
Transwell devices were used with a 0.4-μm-pore polycarbonate 
filter membrane, which allow small and soluble molecules but 
not cells to pass through. Hepa1-6 cells (1.5 × 106) were seeded 
in lower chamber. LV-gra15II-Mφ, LV-Mφ, and Mφ (2 × 106) were 
seeded in the 1% penicillin–streptomycin. After 72 h incubation, 
the Hepa1-6 cells were harvested for total RNA and protein 
detections.
Wound healing assay
The migration of Hepa1-6 cells, cocultured with the three 
groups of macrophages as described above, were assessed 
using the wound healing assay. Hepa1-6 cells (1 ×  106) were 
inoculated in the lower chambers in the 6-well plate, and the 
macrophages (2 × 106) were inoculated in the upper chambers 
at the same time. The upper and the lower chambers were sepa-
rated for culturing. After 24 h of the cell culture with Hepa1-6 
cells nearly at 80% confluence, a 10-µl pipette tip was used to 
make a straight scratch to simulate a wound, and then washed 
twice with PBS. At least three randomly selected fields along 
the scraped line in each well were photographed. Finally, the 
medium in both upper and lower chambers was changed with 
fresh DMEM containing 3% FBS. The upper chamber was 
inserted into the lower chamber for coculture without cellular 
contact. Following 12 and 24 h incubation, the selected fields 
were photographed again. The gap distance was quantitatively 
evaluated using Image-Pro Plus 6.0.
invasion assay
The invasion capability of Hepa1-6 cells after coculturing with 
various transfected Mφ was assessed using transwell assay. Also, 
8-μm-pore polycarbonate filter membrane was used within 
side of the transwell apparatus. The upper chambers were 
pre-covered with Matrigel diluted with culture medium and 
incubated at 37°C overnight according to the manufacturer’s 
instructions. Then, Hepa1-6 (1 × 104) cells were suspended in 
100 μl serum-free DMEM and deposited into the upper chamber 
per well. The lower chamber contained various types of Mφ 
(1 × 106) suspended in 700 µl 10% FBS-supplemented medium. 
After incubation for 24 h, the cells inside of the upper chamber 
were removed using cotton swabs. The cells on the surface of 
the polycarbonate filter membrane were fixed in 10% buffered 
neutral formaldehyde for 15 min and washed twice in PBS. Then, 
the cells were stained with crystal violet for 15 min after drying 
at the room temperature. Before the observation, the cells were 
washed twice in PBS and dried again. The invasion ability of 
cells was quantified by counting the number of cells that have 
invaded the membranes in five randomly selected fields under 
a microscope.
animal care and ethics statement
Female C57BL/6 mice (6  weeks old) were purchased from 
Changzhou Gavens Laboratory Animal Company, China 
(production permit No. Scxk2013-003). All animal care and 
experimental protocols were conducted in strict accordance 
with the Chinese National Institute of Health Guide for the 
Care and Use of Laboratory Animals (1998) and approved by 
the Institutional Review Board of Anhui Medical University 
Institute of Biomedicine (permit No. AMU26-080610). Every 
effort was made to minimize animal suffering during the 
study.
Table 1 | The primers used for qrT-Pcr.
Target Forward primer (5′–3′) reverse primer (5′–3′)
GAR15 CGCTCGAGAATAATTCGGTGGCTTG AGGGATCCTTCATGGAGTTACCGCTGATTG
TNF-α ACGGCATGGATCTCAAAGAC GTGGGTGAGGAGCACGTAGT
IL-12p40 GATGTCACCTGCCCAACTG TGGTTTGATGATGTCCCTGA
iNOS CACCTTGGAGTTCACCCAGT ACCACTCGTACTTGGGATGC
MMP-2 GAATGCCATCCCTGATAACCT GCTTCCAAACTTCACGCTCTT
MMP-9 CCTACTGCGGGCTCTTCT CCTGTAATGGGCTTCCTCT
IL-6 CCGGAGAGGAGACTTCACAG CATTTCCACGATTTCCCAGA
IL-10 GCTCCTAGAGCTGCGGACT TGTTGTCCAGCTGGTCCTTT
TGF-β CTGGATACCAACTACTGCTTCAG TTGGTTGTAGAGGGCAAGGACCT
VEGF CAGGCTGCTGTAACGATGAA AATGCTTTCTCCGCTCTGAA
GAPDH CAACTTTGGCATTGTGGAAGG ACACTTTGGGGGTAGGAACAC
iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; IL-6, interleukin-6; IL-10, interleukin-10.
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Tumor Models
For the subcutaneous tumor model, 100  µl normal saline 
containing 3 × 106 Hepa1-6 cells were subcutaneously injected 
into the right lower inguinal of one naïve mouse. After 3 days, 
a hard mass could be palpated, and the tumor volume reached 
50 mm3. Tumors were seen in all inoculated animals. The mice 
were randomly divided into three groups (10 mice each) as fol-
lows: LV-gra15II-Mφ, LV-Mφ, and normal saline (NS) control. 
On the third and fifth day of post Hepa1-6 inoculation, the mice 
of LV-gra15II-Mφ and LV-Mφ groups received 100 µl NS within 
2.5 × 106 corresponding macrophages through tail vein injection, 
respectively, and the control mice were given the same volume of 
NS. On days 3, 5, 7, and 10 following Hepa1-6 inoculation, tumor 
size was measured using vernier caliper and calculated using the 
formula 0.52 × a × b2 (a, long diameter of the tumor; b, short 
diameter of the tumor). Ten days later, the animals were scarified 
under euthanasia for further analyses.
rna extraction and qrT-Pcr
Total RNA from the cocultured cells, tumors, and spleens were 
extracted using Trizol reagent and reversely transcribed to cDNA 
using Prime Script first Stand cDNA Synthesis Kit according to 
the manufacturer’s instructions. The qRT-PCR was performed to 
examine the expression of TNF-α, IL-12, iNOS, MMP-9, MMP-2, 
IL-10, IL-6, TGF-β, and VEGF using SYBR Premix Ex Taq kit by 
the ABI Prism 7500 sequence detection system according to the 
manufacturer’s guidance. GAPDH gene was used as a reference. 
All the reactions were run in technical triplicates. The relative 
mRNA expression was calculated with the comparative ΔCt 
method using the formula 2−ΔΔCt. The forward and reverse prim-
ers are listed in Table 1.
elisa and nitrite assays
LV-gra15II-Mφ, LV-Mφ, and Mφ were separately seeded in 
6-well plates (2 × 106 cells per well), suspended in 2 ml common 
culture medium, and cultured at 37°C with 5% CO2 for 48 h. Cell 
supernatants were collected and analyzed for cytokine values 
(TNF-α) and NO concentration. IL-6 in the tumor homogenate 
supernatants was also determined by ELISA in accordance with 
the manufacturer’s instructions. The NO content reflected as 
the nitrite concentration was analyzed using the Griess Reagent 
System.
Western blotting analysis
Total proteins were extracted from the Hepa1-6 cocultured with 
the macrophages and separated on 12% SDS-polyacrylamide 
gels. The proteins were then transferred onto nitrocellulose 
membranes. Non-specific binding was blocked with 5% skim 
milk in PBS-Tween-20 (0.1%) for 6  h at room temperature. 
The membranes were then incubated with primary antibodies 
to MMP-9 (1:1,000), MMP-2 (1:1,000), and GAPDH (1:2,000) 
at 4°C overnight and with the horseradish peroxide-conjugated 
secondary antibodies at room temperature for 2 h. ECL kit was 
used to detect the specific signals, and the bands intensity was 
visualized.
immunohistochemical analysis
The tumor tissues from each animal were removed immediately 
under anesthesia and placed in 10% buffered neutral formalde-
hyde. First, the antigen retrieval was executed under high pres-
sure in 10mM EDTA buffer. Second, the samples were incubated 
with primary antibodies to F4/80, CD68, IL-10, TGF-β, VEGF, 
or MHCII at 4°C overnight. Finally, the sample was incubated 
for 45 min with secondary antibodies. Bright-field images were 
photographed and analyzed. The positive macrophages were 
defined by examining F4/80 and CD68 and were counted in 10 
randomly selected fields at ×400 magnification.
statistical analysis
All experiments were replicated three times with similar results. 
All data are expressed as mean  ±  SD and evaluated using a 
two-tailed unpaired Student’s t-test. Statistical significance was 
determined by using GraphPad Prism Software, and P < 0.05 was 
taken as significant.
resUlTs
raW264.7 cell line Was stably 
Transfected
RAW264.7 cells were transfected by LV-gra15II-Mφ or LV-Mφ 
as mock control. The results indicated that the Lv-mediated 
gene transfer system could efficiently transfer GRA15II gene into 
RAW264.7 cells. As shown in Figure 1A, we observed numerous 
green fluorescent cells using the fluorescence microscope. Also, 
FigUre 1 | raW264.7 cells were infected with gra15ii fused to pegFP. (a) Green fluorescent protein can be observed by using the fluorescence 
microscope. Transfection efficiency was measured by flow cytometry. (b) LV-gra15II-Mφ cells surface mark, programmed death ligand 1 (PD-L1) and CD80 
determined by flow cytometry. The expressions of PD-L1 and CD80 in LV-gra15II-Mφ were increased compared with LV-Mφ. (c) Statistical analysis of mean 
fluorescence intensity (MFI) of markers shown in (b) (*P < 0.05).
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we detected the transfection efficiency using flow cytometry. 
The efficiency of LV-gra15II-Mφ, LV-Mφ, and Mφ was 90.02, 
97.1, and 0.00%, respectively.
Toxogra15ii Drove raW264.7 cells to M1
Compared with LV-Mφ, LV-gra15II-Mφ expressed high level 
of PD-L1 (P < 0.01) and CD80 (P < 0.01) determined by FCM 
(Figures 1B,C). The relative TNF-α (P < 0.05), IL-12 (P < 0.05), 
and iNOS (P < 0.001) mRNA expression levels in LV-gra15II-Mφ 
were significantly increased compared with LV-Mφ (Figure 2A). 
As for the cell supernatants, the inflammatory factors NO 
(P < 0.001) and TNF-α (P < 0.01) sharply rose in macrophages 
infected with LV-gra15II, which is in accordance with the mRNA 
expression (Figure 2B).
lV-gra15ii-Mφ alleviated In Vivo 
Proliferation of the Tumor cells
Tumor was palpable, and tumor size was about 50  mm3 
3 days after Hepa1-6 cells subcutaneous injection in the mice 
(Figure  3A). Compared with the control group (LV-Mφ), on 
days 7 (P < 0.001) and 10 (P < 0.001) post Hepa1-6 inocula-
tion, the tumor proliferation was markedly inhibited in mice 
that received twice LV-gra15II-Mφ treatments (Figures 3B,C). 
This result was obtained by measuring the size of the tumor 
(Figure  3C). Examination of frozen sections by fluorescence 
microscopy revealed that both LV-gra15II-Mφ and LV-Mφ 
reached the tumor site and remained in it for at least 72  h 
after intravenous injection (Figure  3D). The TAMs infiltra-
tion of solid tumor was examined by immunohistochemistry. 
Figure  4 showed that the number of macrophages in tumor 
microenvironment was decreased in the LV-gra15II-Mφ treated 
group, and reduced expression of IL-10, TGF-β, and VEGF in 
tumor tissues and increased expression of MHCII molecule 
in the animals that received LV-gra15II-Mφ inoculations, 
compared with the group treated with LV-Mφ. The data 
were further verified by using qRT-PCR. Consistent with the 
immunohistochemistry assay, relative mRNA expressions of 
IL-10 (P < 0.01), TGF-β (P < 0.05), and VEGF (P < 0.05) were 
significantly decreased, and iNOS (P < 0.05) was remarkably 
elevated (Figure  5A). More significantly, IL-6 production, 
which has been considered to be closely associated with 
tumorigenesis in tumor microenvironment, was impaired. 
The mice with LV-gra15II-Mφ injection exhibited a notable 
decrease in levels of mRNA coding for IL-6 (P < 0.05) when 
compared with the control group (Figure  5B). Parallel IL-6 
expression results (P < 0.05) were confirmed by ELISA in the 
tumor homogenate supernatants (Figure 5B).
lV-gra15ii-Mφ have effects in spleen
Observation of frozen sections of spleen tissue under the 
fluorescence microscope revealed that both LV-gra15II-Mφ and 
LV-Mφ reached spleen and survived in this site after intrave-
nous injection (Figure 6A). Mice injected with LV-gra15II-Mφ 
exhibited notable increase in mRNA transcription of TNF-α 
(P < 0.01) and IL-12 (P < 0.05), and decrease in IL-6 (P < 0.01) 
and IL-10 (P  <  0.01), in comparison to mice injected with 
LV-Mφ (Figure 6B).
lV-gra15ii-Mφ Weakened the Migration 
and invasion of hepa1-6 In Vitro
Cocultured migration and invasion of Hepa1-6 cells with 
LV-gra15II-Mφ were inhibited. Obviously, in the wound healing 
assay, the relative Hepa1-6 cell migration was notably decreased 
in the LV-gra15II-Mφ coculture group (P < 0.001) compared with 
the LV-Mφ coculture group (Figures 7A,B). Similar results were 
obtained in the invasion assay, the migrated numbers of Hepa1-6 
cells were declined in the group cocultured with LV-gra15II-
Mφ (P <  0.001) (Figures  7C,D). The MMP-9 (P <  0.05) and 
FigUre 3 | lV-gra15ii-Mφ inhibited tumor growth in the hepa1-6 planted tumor model. (a) Experimental outline for inhibitory tumorigenesis by 
administration of LV-gra15II-Mφ in tumor-bearing mice. LV-Mφ and saline were used as control. (b) Representative tumor in different groups. (c) Size of tumor. Data 
are representative of three independent experiments (***P < 0.001). (D) Tumor frozen sections were observed under the fluorescence microscope. Samples were 
collected 72 h after injection of LV-gra15II-Mφ, LV-Mφ, or normal saline (NS). The fluorescence microscopy fields shown are representative ones (10 fields per tumor, 
3 tumors per group).
FigUre 2 | analysis of the iconic cytokines of the classically activated macrophages. (a) The mRNA expression of LV-gra15II-Mφ upregulated TNF-α 
(P < 0.05), IL-12 (P < 0.05), and inducible nitric oxide synthase (iNOS) (P < 0.001), respectively, compared with LV-Mφ. (b) The concentration of nitric oxide (NO) 
and TNF-α in cell supernatants was tested with enzyme-linked immunosorbent assay (*P < 0.05, **P < 0.01).
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FigUre 4 | immunohistochemical analysis of tumor tissues after treatment with lV-gra15ii-Mφ. The macrophages were examined by immunostaining with 
the antibodies to F4/80 and CD68, and the number of these cells was counted at ×400 magnification. Data represent the mean Mφ number per field ± SD (10 fields 
per tumor, 3 tumors per group). The expression of interleukin-10 (IL-10), TGF-β, VEGF, and major histocompatibility complex II (MHCII) evaluated by immunostaining, 
and the number of IL-10-positive, TGF-β-positive, VEGF-positive, and MHCII-positive cells were counted (*P < 0.05, **P < 0.01, ***P < 0.001).
FigUre 5 | relative mrna expression levels of immunosuppressive molecules and cytokines in tumor samples were assayed. (a) The relative mRNA 
expressions of interleukin-10 (IL-10) (P < 0.01), TGF-β (P < 0.05), and VEGF (P < 0.05) were significantly decreased, and inducible nitric oxide synthase (iNOS) 
(P < 0.05) was remarkably increased in mice that received LV-gra15II-Mφ. (b) Interleukin-6 (IL-6) expression in both mRNA and protein was decreased in group 
LV-gra15II-Mφ.
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MMP-2 (P  <  0.05) mRNA expression levels in the Hepa1-6 
cells were downregulated in the LV-gra15II-Mφ coculture 
group (Figure 7E). To verify the mRNA data, we identified the 
MMP-9 and MMP-2 expression by Western blotting. The results 
revealed that the levels of MMP-9 and MMP-2 were lowered in 
LV-gra15II-Mφ coculture group (Figure 7F). However, there was 
no noticeable apoptosis of Hepa1-6 cells that were cocultured 
with LV-gra15II-Mφ (Figure 7G).
FigUre 6 | lV-gra15ii-Mφ reached spleen tissues, and relative mrna expression levels of cytokines in spleen samples were assayed. (a) Spleen 
frozen section were observed under the fluorescence microscope. Samples were collected 24 h after injection of LV-gra15II-Mφ, LV-Mφ, or normal saline (NS). The 
fluorescence microscopy fields shown are representative ones (10 fields per tumor, 3 tumors per group). (b) The relative mRNA expressions of TNF-α (P < 0.01) and 
IL-12 (P < 0.05) were significantly increased, interleukin-6 (IL-6) (P < 0.05) and interleukin-10 (IL-10) (P < 0.05) were remarkably decreased in mice that received 
LV-gra15II-Mφ.
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DiscUssiOn
Macrophages and related mononuclear phagocytes are the 
preferred host cells of T. gondii in  vivo, although the intracel-
lular parasite can infect any sort of nucleated cells. Macrophage-
centered innate immune response of host to T. gondii may 
determine the outcomes of its infection. One of the recent key 
findings revealed that type II strains of Toxoplasma evoked a gene 
expression profile quite close to classically activated macrophages 
(M1) that induces strong IL-12- and Th1-predominant immunity 
crucial to the consequences of chronic infection (23). Previous 
investigators found that T. gondii-derived genotype-associated 
effector of ToxoGRA15II is responsible for efficient induction of 
M1 phenotype (18), which is featured by presenting high NO, 
TNF-α, iNOS, and IL-12p40 (5, 8, 19–21, 24), involving in host 
innate immunity and Th1-dominant inflammatory response to 
the pathogen. Our previous study showed that ToxoGRA15II is 
able to induce RAW264.7 polarization to M1, leading to distinct 
attenuation of liver fibrotic process after M1 transferring to mice 
infected with Schistosoma japonicum (21).
Chronic inflammation is known to contribute to cancer pro-
gression (25, 26). TAMs, recruited by chemokines CCL2, CCL5, 
and CXCL, are derived from circulating monocyte precursors 
(27) and are the most important regulators of tumorigenesis (28, 
29), which may serve as one of the hallmarks of cancer. It has 
been well documented that TAMs promote the development of 
tumor, and its infiltration is highly correlated with poor prognosis 
(7, 30, 31). Here, we reported an apicomplexan parasite-derived 
peptide ToxoGRA15II, which may alter tumor microenvironment 
to inhibit tumor growth transplanted with Hepa1-6. In the pre-
sent study, LV-gra15II-Mφ was injected through veins alleviated 
proliferation of the tumor in mice. Thereby, we found that M1 
phenotype evoked by ToxoGRA15II successfully reduced the vol-
ume of tumors and attenuated the infiltration of TAMs in tumor 
tissues of murine model. The number of macrophages labeled by 
F4/80 and CD68 in the group treated with LV-gra15II-Mφ was 
significantly lower than those in the group that received LV-Mφ. 
For instance, once M1 phenotype successfully activated in tumor 
microenvironment may play a significant role in restriction of 
tumor progression (27). The number of macrophages expressing 
MHCII increased in the animals with LV-gra15II-Mφ administra-
tion when compared to those with LV-Mφ, indicating an improved 
antigen-presenting capability. It has been well confirmed that M1 
produce high levels of pro-inflammatory cytokines of IL-12 and 
NO, and characterized by MHCII molecules and functions as a 
key population of antitumor cells (32, 33).
FigUre 7 | The migration and invasion of hepa1-6 cells were weakened after coculturing with lV-gra15ii-Mφ. (a,b) The migration of Hepa1-6 cells in the 
wound healing assay taken 24 and 48 h after coculture of Hepa1-6 with Mφ. (c) The representative images of Hepa1-6 cells migration after coculturing with 
LV-gra15II-Mφ (×100). (D) The number of migrated Hepa1-6 cells. (e) Western blotting analysis of matrix metalloproteinase (MMP)-9 and MMP-2 expression. (F) The 
mRNA expression of MMP-9 and MMP-2 in Hepa1-6 cells. (g) MTS assay in LV-gra15II-Mφ and LV-Mφ groups (*P < 0.05, ***P < 0.001).
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RAW264.7 macrophage used here for transfusion is a com-
mon cell line of mouse macrophages for the study of immune 
responses to microbes and their products. However, we did 
not observe any remarkable allogeneic response of recipient 
C57BL/6 mice to the transferred cells. A possible explanation 
is that cancers are characterized by a compromised immu-
nogenicity due to their genetic instability and epigenetically 
downregulated MHC receptor (34, 35). RAW264.7, as a cancer 
cell line after a long-term in vitro passage, should have a feature 
of low antigenicity and fail to induce strong allogeneic response 
of recipient C57BL/6 mice that had been concomitantly immu-
nocompromised by tumor implantation. In the present study, 
neither C57BL/6 mice inoculated with LV-gra15II-Mφ nor with 
LV-Mφ mock macrophages presented distinct difference of gen-
eral body condition compared to those of normal saline control, 
suggesting the tolerance of recipient’s C57 BL/6 mice to trans-
ferred cells, and the tumor growth restriction was not caused by 
allogeneic response of transferred macrophages. Additionally, 
we used MHCII monoclonal antibodies to recognize MHCII 
alleles expressed by transferred cells and the recipient’s cells (C57 
BL/6 peritoneal exudate macrophages), respectively. The result 
showed that both cells were strongly recognized by the MHCII 
monoclonal antibodies used (data not shown). Taken together, 
we believe that passive transferring of RAW264.7 would not be 
able to evoke allogeneic response that is strong enough to injure 
the recipient animals.
The TAMs, which are mostly similar to alternatively activated 
macrophages (M2) in phenotype, are reeducated by tumor-
derived factors and usually act as pro-tumor growth cells (36, 
37). Cytokine and chemokine profiles in tumor microenviron-
ment control the bias of infiltrating macrophages. To explore the 
putative retraining of the TAMs in tumor tissues, we detected the 
expressions of immune factors and those associated with tumor 
angiogenesis, such as IL-10, TGF-β, and VEGF. Furthermore, our 
results showed that mice that were treated with LV-gra15II-Mφ 
presented an obvious reduction of the molecules that are related 
to the downregulation of immune response. Previous literatures 
indicated that IL-6 is involved in facilitation of tumor growth 
via regulating all hallmarks of cancer and multiple signaling 
pathways (38, 39). Here, we noted a particular decrease of IL-6 
production, which might also contribute to alteration of tumor 
microenvironment by M1 transferring.
In the present investigation, we tracked the in  vivo fate 
of the LV-gra15II-Mφ and found the macrophages inoculated 
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